Abstract
Context The gut microbiome has been shown to be in a bidirectional interaction with type 2 diabetes medications that have been in clinical use for several decades. However, the bidirectional effects of novel type 2 diabetes drugs semaglutide, empagliflozin, and the gut microbiome have yet to be clearly described.
Objective We investigate the effect of semaglutide and empagliflozin initiation on the gut microbiome of type 2 diabetes patients. In addition, we analyze whether the pre-treatment gut microbiome can predict the treatment efficacy.
Methods Gut microbiome fecal samples donated at four timepoints (Baseline, Month 1, Month 3; Month 12) were studied using 16S ribosomal RNA gene sequencing and analysis. Subjects additionally donated plasma and urine samples for quantitative measurement of clinical markers before treatment initiation and at Months 3 and 12. Repeated measures ANOVA paired with paired t-tests were used to analyze the effects of drug initiation on the gut microbiome. Pearson correlation was used to identify microbial features associated with the change in clinical parameters.
Results Semaglutide and empagliflozin use is associated with changes in the gut microbiome after treatment initiation, but changes in microbial diversity were not detected. The baseline gut microbiome predicted changes in glycohemoglobin for semaglutide and empagliflozin users.
Conclusion Our findings suggest that semaglutide and empagliflozin impact the gut microbial community during treatment. In addition, the baseline gut microbiome can predict semaglutide treatment effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Estonian Research Council grant (PRG1414 to E.O. and IUT2041 to V.V.) and an EMBO Installation grant (No. 3573 to E.O.). A. K. was supported by the University Tartu Foundation (CWT Estonia Traveling Scholarship) and the Ministry of Education and Research of Estonia (Kristjan Jaak National Scholarship). K.L.K was supported by the European Regional Development Fund (Smart Specialization PhD Scholarships).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee of the University of Tartu Number of Approval: 290/T-20 Committee Meeting: 18.02.2019 Members of the Committee: Chairman Kadri Tamme University of Tartu, Faculty of Medicine, Lecturer in Anaesthesiology and Intensive Care Vice-chairman Kristi Louk University of Tartu, Faculty of Arts and Humanities, Project Manager Members Diva Eensoo National Institute for Health Development, Researcher Naatan Haamer University of Tartu Hospital, Pastoral Counselor Malle Kuum University of Tartu, Faculty of Medicine, Lecturer in Pharmacology / Research Fellow in Pharmacology Liis Leitsalu University of Tartu, Faculty of Science and Technology, Research Fellow Maire Peters University of Tartu, Faculty of Medicine, Associate Professor in Genetics Mare Remm Tartu Health Care College, Department of Radiography and Bioanalytics Pille Taba University of Tartu, Faculty of Medicine, Professor in Neurology / Head of Department of Neurology and Neurosurgery of University of Tartu Hospital Maria Tamm University of Tartu, Faculty of Medicine, Research Fellow in Experimental Psychology Oivi Uibo University of Tartu, Faculty of Medicine, Associate Professor of Paediatric Gastroenterology Vahur Oopik University of Tartu, Faculty of Medicine, Professor of Exercise Physiology Decision: Approve the Study Title of the Study: Beneficial Treatment Effects of Novel Antidiabetic Medications to the Function of Adrenal Glands and Gut Microbiome of Type 2 Diabetes Patients Principal Investigator (Institution): Vallo Volke (University of Tartu Hospital, Internal Medicine Clinic, L. Puusepa 8, 50406 Tartu) Documents of Approved by the Committee: Application sent for approval to the Research Ethics Committee of the University of Tartu, 05.03.2019 Approval of the study by University of Tartu Hospital Patient Informed consent form, 02.04.2019 Patient questionnaire form, 05.03.2019 Instructions for urine sample collection Instructions for fecal sample collection CVs of the study personnel (V. Volke, E. Org, I. Reppo, T. Eglit, M. Lubi, O. Gusseva, S. Matjus, K. Tammiksaar, K. Lull, O. Aasmets) End of the Study: 31.12.2023 Chairman of the Committee : Kadri Tamme /signed digitally/ Secretary of the Committee: Kaire Kallak /signed digitally/ Released: /date of the last digital signature/ ______________________________________________________________________________ University of Tartu tel 737 6215 Grant Office e-mail eetikakomitee{at}ut.ee Lossi 3 www.ut.ee/teadus/eetikakomitee 51003 Tartu
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data generated in this study have been deposited in the European Genome-Phenome Archive database (https://www.ebi.ac.uk/ega/) under accession code xxx. This study was approved by the Research Ethics Committee of the University of Tartu (approval No. 290/T-20).
